Brief: Astrazeneca Pharma India Receives Permission To Import Benralizumab (Fasenra) For Additional Indication
16/07/2026 09:56
BRIEF-Astrazeneca Pharma India Receives Permission To Import Benralizumab (Fasenra) For Additional Indication July 16 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:
ASTRAZENECA PHARMA INDIA - RECEIVES PERMISSION TO IMPORT BENRALIZUMAB (FASENRA) FOR ADDITIONAL INDICATION
Source text: ID:nBSE4Rs2Sz
Further company coverage: ASTR.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma India Receives Permission To Import And Sell Trastuzumab Deruxtecan For Additional Indication
Brief: Astrazeneca Pharma Says Bhavana Agrawal Resigns As CFO
Brief: Astrazeneca Pharma India Receives Permission To Import And Sell Benralizumab For Additional Indication
Brief: Astrazeneca Pharma India Receives Permission To Import Benralizumab (Fasenra) For Additional Indication
Brief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan